Table 1.
Cetuximab-treated patient’s characteristics (N = 90).
| Sex | [N] | [%] |
|---|---|---|
| Male | 63 | 70.0 |
| Female | 27 | 30.0 |
| Age (years) | [N] | [%] |
| Median | 64 | |
| Range | 24–79 | |
| Primary Tumor Location | [N] | [%] |
| Rectum | 26 | 28.9 |
| Rectosigmoid | 6 | 6.7 |
| Sigma | 28 | 31.1 |
| Descending colon | 8 | 8.9 |
| Lienal flexure | 3 | 3.3 |
| Transverse colon | 4 | 4.4 |
| Hepatic flexure | 1 | 1.1 |
| Ascending colon | 8 | 8.9 |
| Coecum | 6 | 6.7 |
| Primary Tumor T | [N] | [%] |
| NA | 13 | 14.4 |
| 1 | 0 | 0.0 |
| 2 | 6 | 6.7 |
| 3 | 54 | 60.0 |
| 4 | 17 | 18.9 |
| Primary Tumor N | [N] | [%] |
| NA | 13 | 14.4 |
| 0 | 21 | 23.3 |
| 1 | 26 | 28.9 |
| 2 | 29 | 32.2 |
| 3 | 1 | 1.1 |
| Resection of Primary | [N] | [%] |
| Yes | 77 | 85.6 |
| No | 13 | 14.4 |
| RAS Testing | [N] | [%] |
| KRAS exon2 | 75 | 83.3 |
| Extended RAS | 15 | 16.7 |
| Number of Evaluated Primary Tumors (N = 88) | [N] | [%] |
| Right | 19 | 21.6 |
| Left | 69 | 78.4 |
| Number of Metastases Evaluated by IHC (N = 29) | [N] | [%] |
| Liver | 17 | 58.6 |
| Lung | 2 | 6.9 |
| Lymphnode | 2 | 6.9 |
| Cerebellum | 1 | 3.4 |
| Skin | 1 | 3.4 |
| Ovarium | 1 | 3.4 |
| Peritoneum | 3 | 10.3 |
| Soft tissue | 1 | 3.4 |
| Mesocolon | 1 | 3.4 |
| Number of Metastases Evaluated by IHC (N = 29) | [N] | [%] |
| Right | 11 | 37.9 |
| Left | 18 | 62.1 |
| Abbreviation(s): immunohistochemistry (IHC) |